Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongren-Dahuoluo Bolus (also known as Tongren Dahuoluowan) is a traditional Chinese medicine (TCM) formulation being evaluated for the treatment of knee osteoarthritis, specifically in patients presenting with liver-kidney deficiency syndrome and/or cold-dampness arthralgia syndrome. Developed and studied by Guang'anmen Hospital of China Academy of Chinese Medical Sciences, this complex herbal formulation is administered orally as a large pill (bolus). It is currently being investigated in Phase 4 clinical trials to assess its long-term safety, tolerability, and efficacy in improving symptoms of knee osteoarthritis compared to placebo over a 24-week research cycle. The formulation is traditionally used in China for various musculoskeletal and neurological conditions, including stroke and rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongren-Dahuoluo Bolus.